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Summary
Since the mid-1990s, public health laboratories have improved tuberculosis (TB) test performance, which has contributed to
the resumption of the decline in TB incidence in the United States. However, to eliminate TB in the United States, further
improvements are needed in laboratory services to support TB treatment, prevention, and control. A critical step is the develop-
ment of an integrated system that ensures prompt and reliable laboratory testing and flow of information among laboratorians,
clinicians, and TB-control officials. Challenges to developing such a system include 1) establishing lines of communication among
laboratorians, clinicians, and TB-control officials; 2) expediting reporting of laboratory results, which can avoid delayed or
inappropriate treatment and missed opportunities to prevent transmission; 3) developing evidence-based recommendations for use
of new laboratory technologies; 4) maintaining staff proficiency in light of declining numbers of specimens to test, workforce
shortages, and loss of laboratory expertise; and 5) upgrading laboratory information systems and connecting all partners. The
report of the Association of Public Health Laboratories Task Force presents a framework to improve the future of TB laboratory
services and describes the role of the laboratory in TB treatment and control, Task Force processes, general principles and bench-
marks, and steps for the dissemination of the Task Force recommendations. This MMWR expands on the Task Force report by
describing specific actions and performance measures to guide development and implementation of an integrated system for
providing TB laboratory services. CDC and the Association of Public Health Laboratories have developed these guidelines so that
laboratorians, clinicians, public health officials, administrators, and funding entities can work together to ensure that health-care
providers and TB-control officials have the information needed to treat TB patients, prevent TB transmission, and ultimately
eliminate TB in the United States.
Introduction
Approximately one third of the world’s population is in-
fected with Mycobacterium tuberculosis (1), and despite an over-
all decline in tuberculosis (TB) cases in the United States, TB
continues to pose substantial social, public health, and eco-
nomic costs. In 2003, approximately 15,000 new cases of TB
were reported in the United States (2), and an estimated 9–14
million persons have latent TB infection with attendant risk
of future disease (3).
The laboratory is an essential part of the diagnosis, treat-
ment, prevention, and control of TB (4). Delays in labora-
tory confirmation of TB and reporting of drug-susceptibility
results can lead to delays in initiation of therapy, prolonged
infectiousness, inappropriate therapy, and missed opportuni-
ties to prevent transmission (5,6). In the early 1990s, such
delays contributed to the resurgence of TB and the emergence
of multidrug-resistant TB (MDR TB) in the United States (5,6).
In response to the threat of MDR TB, CDC increased fund-
ing to strengthen public health laboratories and placed em-
phasis on providing prompt and reliable laboratory results
(5,7). Since the early 1990s, public health laboratories have
made substantial strides in improving test performance
(7–9). These improvements contributed to the resumption of
the decline of the incidence of TB in the United States and a
decrease in MDR TB cases (10,11) since the mid-1990s.
2 MMWR April 15, 2005
Nevertheless, TB outbreaks still occur and MDR TB contin-
ues to spread. For TB to be eliminated in the United States,
further improvements in laboratory services are needed, and
these advances need to be translated into improvements in
the treatment, prevention, and control of TB (11).
Prompted by an Institute of Medicine (IOM) report (4)
and by the growing need for high-quality, cost-effective TB
laboratory services in a time of declining case rates and shift-
ing public health priorities, the Association of Public Health
Laboratories (APHL) and CDC commissioned the APHL Task
Force on the Future of TB Laboratory Services in 2002. The
Task Force includes representatives from APHL, CDC, pub-
lic health laboratories, clinical laboratories, and the National
Tuberculosis Controllers Association (NTCA).
The Task Force’s primary goal was to develop a framework
to improve TB control by promoting optimal use of labora-
tory services and effective information tracking and report-
ing. The Task Force defined concerns critical to laboratorians
performing TB testing, public health officials, TB-control
officials, and health-care providers and created benchmarks
and outcome measures to promote delivery of prompt, high-
quality, state-of-the-art laboratory services. This report sum-
marizes the recommendations of the Task Force and describes
in greater detail specific actions and performance measures to
guide development and implementation of an integrated sys-
tem for providing TB laboratory services. This report also pro-
vides information on the scientific basis of the
recommendations.
Background
The increased incidence in TB cases during the mid-1980s–
early 1990s prompted an acceleration of TB-control efforts
and focused attention on the role of the mycobacteriology
laboratory in supporting patient management and TB-
control efforts (4–6). Altogether, TB-related costs approach
$1 billion each year in the United States (12). In addition,
human immunodeficiency virus (HIV) infection is one of the
greatest risk factors for development of TB (13). Prompt and
reliable laboratory test results are critical for HIV-infected TB
patients because of differences in the clinical analysis and more
rapid course of the disease (14).
Since 1995, CDC has provided approximately $8 million/
year to state and local public health laboratories to improve
TB laboratory services (7) and has placed increased emphasis
on reliable and prompt results (5,7). The latter included
efforts to reduce the delays associated with laboratory testing
for M. tuberculosis, to improve communication between
laboratorians and health-care providers, and to maintain a
trained workforce. Recommendations developed during the
mid-1990s for TB laboratory services (9,15,16) remain valid
and include
• prompt delivery of specimens to the laboratory;
• use of rapid, state-of-the-art methods (e.g., fluorescence
microscopy, liquid media, and rapid identification
methods);
• reporting of smear results to health-care providers within
1 day;
• reporting of culture identification of M. tuberculosis com-
plex within 21 days;
• reporting of drug-susceptibility test results within 30 days;
and
• reporting of all positive test results to the specimen
submitter within 1 working day from the date of report.
Reports demonstrate that during the 1990s, the emphasis
on rapid diagnosis and other improvements in laboratory ser-
vices contributed substantially to the resumption in the de-
cline of the incidence of TB and the decrease in MDR TB
cases nationwide (4,10). TB incidence is limited in certain
areas of the United States, but other regions, especially those
with substantial immigrant populations, still have high
caseloads (4,17). Regardless of caseloads and incidence, effec-
tive TB treatment and control require prompt and reliable
laboratory services.
Laboratory confirmation of a TB case often depends on a
network of laboratories providing testing for diagnosis, treat-
ment, and monitoring of therapy outcomes (18–20). How-
ever, information is limited regarding the capabilities,
capacities, and interactions of the approximately 2,000 TB
laboratories at state and local levels and in the private and
public sectors. For example, all 50 state public health labora-
tories perform a level of TB testing and usually serve as the
major referral and reference laboratories for culture identifi-
cation and M. tuberculosis drug-susceptibility testing (7,8); in
addition, certain medical centers and commercial laborato-
ries provide advanced TB testing services (21,22). However,
the precise contribution of each to TB laboratory services
within a jurisdiction is unknown. Approximately 80% of ini-
tial TB laboratory testing (e.g., smear and culture inocula-
tion) is performed in the private sector, whereas >50% of
species identification and drug-susceptibility testing is con-
ducted in public health laboratories (21).
Within a network of laboratories, referring specimens or
isolates to other laboratories for testing is common and often
involves both the private and public sectors (18–20,22–26).
Referral of specimens and cultures can lead to delays in test-
ing, reporting, and treatment initiation for TB patients with
smear-positive or smear-negative/culture-positive results (24).
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Reimbursement models also complicate this process because
they might contradict the common practice in which a speci-
men from a patient with a smear-positive result identified at a
local site is referred to a full-service laboratory for culture.
The complexities of TB testing and referral underscores the
need for an integrated system that emphasizes efficient flow
of specimens and information between public health and
private-sector laboratorians, clinicians, and TB-control
officials.
Challenges
Improving TB laboratory services and developing a new,
integrated approach is complicated by concerns regarding
funding, communication, turnaround times, technology,
workforce competence, information management systems, and
maintaining proficiency standards.
Funding
Because TB laboratory services are provided by both public
and private laboratories and supported through a combina-
tion of private-sector dollars, Medicare and Medicaid pay-
ments, and local, state, and federal funds (4,7,12), the actual
cost of providing these services is difficult to estimate. Levels
of local, state, and federal funding for TB laboratories have
remained constant or have decreased during recent years, and
federal funding levels for state public health laboratories to
improve TB testing have remained constant at approximately
$8 million/year since 1995 (5,7).
Communication
Delays in referring specimens and reporting information
can lead to delays in diagnosis, disease treatment and control,
and surveillance activities (7,24–26). To optimize TB diag-
nostic, treatment, and control activities, the flow of specimens
and information among laboratorians, clinicians, and TB-
control officials should be efficient and well-coordinated. This
will require increased communication and coordination among
state public health laboratories, clinical laboratories, clinicians,
and TB-control programs. Advances in information technol-
ogy promise to speed the flow of information among key per-
sons, thereby enhancing disease reporting and epidemiologic
analysis of disease trends. However, resources to develop and
install modern, integrated, compatible, electronic informa-
tion systems are limited (27).
Turnaround Times
Rapid detection, species identification, and testing for drug
resistance are necessary to control TB among patients and
populations. After CDC recommendations were published in
1993 (15), the majority of public and private laboratories be-
gan using the recommended rapid methods (7–9,22,23,28).
However, approximately one third of laboratories have had
difficulty meeting the recommended turnaround times, par-
ticularly for drug-susceptibility testing (7,28). A recent Cali-
fornia study determined that 1) lengthy specimen transport
times and the practice of conducting periodic, as opposed to
daily, TB testing were major causes of delay in TB reporting;
2) delays varied by test type and by the type of laboratory
performing testing; and 3) laboratory TB-test reporting often
failed to conform to national guidelines and California regu-
lations (24). A direct correlation existed between reporting
delays and treatment initiation (24).
Technology
Certain technologic advances (e.g., nucleic acid amplifica-
tion testing [NAAT], fluorescence in situ hybridization, or
fluorescence high-performance liquid chromatography
[HPLC] of mycolic acids) can contribute substantially to TB
treatment and control by providing faster laboratory results
(29,30). Such rapid methods will be needed to meet the Healthy
People 2010 objective 14-14 of 2 days of average turnaround
time for laboratories to confirm and report 75% of culture-
confirmed TB cases (31). However, no well-validated testing
algorithms are available to guide programs in adopting or us-
ing these new technologies in laboratory and program set-
tings with varying TB incidence, although general
recommendations exist for use of NAAT to detect
M. tuberculosis (32).
Workforce Competence
The United States is experiencing laboratory workforce
shortages ranging from 8% to >20% in different parts of the
country, and expertise is being lost as increasing numbers of
experienced staff reach retirement age (33). Multiple training
programs for clinical laboratory scientists have closed. In the
face of worker shortages, vacant positions are sometimes filled
by staff who lack training in complex laboratory science.
Information Management Systems
Operation of a modern laboratory requires integrating an
information management system into the majority of labora-
tory activities, including inventory management, specimen
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tracking, test-result reporting, and information sharing with
clinicians and public health officials. State-of-the-art labora-
tory information management systems are available that can
improve the quality and organization of laboratory data and
speed the flow of information to those who have a need to
know. However, the majority of laboratories have either not
yet implemented such systems, or they use systems that are
not fully compatible with information management programs
of TB-control officials or clinicians.
Maintaining Proficiency Standards
As TB incidence declines and as correspondingly fewer cases
are detected and fewer specimens tested, maintaining profi-
ciency in TB-control activities will become more difficult
(19,20). In addition, TB-control activities will become more
expensive because of the loss of economies of scale. Recogniz-
ing this, IOM recommended that TB elimination activities
be regionalized to provide better access to and more efficient
use of clinical, epidemiologic, and other technical services (4).
The concept of regionalizing laboratory services was further
developed in a consultant’s report (7), included as an appen-
dix in the IOM report (4), which recommended that these
matters be considered by a special committee of APHL. Dur-
ing initial deliberations, the Task Force made three observa-
tions: 1) regionalization was too simplistic as a generic solution
to meet the TB-testing needs of diverse populations across the
United States; 2) service models emphasizing coordination
and collaboration among laboratories within and between
jurisdictions were needed; and 3) principles, benchmarks, and
outcome measures were required to guide development of TB
laboratory systems.
Process
APHL convened the Task Force in October 2002. Mem-
bers represented public health programs from states with dif-
ferent population sizes and TB incidence, hospital and
commercial laboratories, and CDC. The Task Force crafted a
set of principles to guide development of benchmarks, which
were specific actions considered essential to improving labo-
ratory TB services and capable of being assessed by outcome
measures.
An overview of Task Force activities was presented in
December 2002 at the National Conference on Laboratory
Aspects of Tuberculosis in San Francisco, California. Confer-
ence attendees, including laboratory administrators, bench
laboratorians, clinicians, and TB-control officials, expressed
support for the Task Force and its mission, as evidenced by
discussion questions and conference evaluations. In February
2003, a summary of Task Force activities and preliminary
benchmarks were presented to the federal Advisory Council
for the Elimination of Tuberculosis (ACET). During a subse-
quent meeting, Task Force members evaluated models of net-
work collaboration to further develop and refine the
benchmarks and outcome indicators.
Preliminary Task Force recommendations were presented
to APHL and NTCA members at their respective annual meet-
ings in June 2003. In February 2004, ACET voted to for-
mally endorse and support the APHL Task Force report, and
in May 2004, APHL published the report (34). The recom-
mendations are being presented also to other key stakeholders
(e.g., the American Society for Microbiology [ASM] and the




The Task Force recommendations are intended to improve
TB control through the optimal use of laboratory services and
effective reporting and tracking of information.
Guiding Principles
• TB elimination is a public health imperative.
• Effective TB control depends on an integrated system that
includes clinicians, laboratorians, and TB-control officials.
• TB control depends on effective public-private
partnerships.
• Effective TB control requires a network of public and
private laboratories performing testing for diseases of
public health importance.
• Public health laboratorians should lead the development
of the laboratory network and should facilitate commu-
nication among laboratorians, clinicians, and TB-control
officials.
• Effective TB control requires prompt, complete, and
accurate communication among the laboratory systems,
TB-control programs, and health-care providers.
• Each jurisdiction should ensure access to appropriate levels of
quality TB testing and complete, prompt reporting.
According to these principles, the laboratory has more active
and integral responsibilities in treatment and control efforts
through coordinated testing and prompt communication of
information to providers and public health agencies to ensure
appropriate patient management.
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Organization of Laboratory Services
Provision of laboratory services is a jurisdictional concern
because of reporting requirements and legal, programmatic,
and financial factors, and because the need for laboratory ser-
vices varies substantially among the diverse state and local treat-
ment and control programs. Within each jurisdiction,
laboratorians and TB-control officials should work together
to determine how to maximize resources to obtain prompt,
reliable test results.
Recommended Benchmarks
To Improve Laboratory TB Services
and TB Control
Implementation of the following actions and base perfor-
mance measures will require new, more effective partnerships
among clinicians, TB-control officials, and public health and
clinical laboratorians.
Capacity and Capability Assessment
Ongoing assessment of available TB laboratory services
should be performed to determine the status and capacity of
services and to identify unmet needs, obstacles to obtaining
laboratory services, and opportunities for improvement. Al-
though data are intended primarily for local use, they might
also improve understanding of laboratory capacity and capa-
bility for TB testing nationally. A standardized assessment tool
should be developed to ensure data are collected consistently.
A list of key information to be collected is provided (Box 1).
Cost Analysis
An assessment of the actual costs of providing TB labora-
tory services should be performed. Because the cost of identi-
fying individual cases increases as the number of cases declines,
the cost of services probably will vary from one jurisdiction to
another. A standardized cost-assessment tool should be devel-
oped to facilitate comparison of data nationally and across
regions.
Cost assessment should include expenditures incurred by
laboratories, public and private health-care providers, and TB-
control programs to 1) provide optimal specimen transport
and referral systems; 2) obtain laboratory testing services that
meet recommended turnaround times; 3) implement new TB-
test technologies in public and private laboratories, as appro-
priate; 4) provide training for laboratorians and health-care
providers; and 5) optimize use of conventional and electronic
communication systems, including computers and laboratory
information management systems, to facilitate prompt flow
of information among laboratorians, clinicians, and TB-
control officials.
• Identify all laboratories providing TB testing services.
• For each in-state and out-of-state laboratory, document
— name, location, organization, director, and contact
information;
— for whom service is provided (e.g., customers or
constituency);
— levels (i.e., types) of services provided;
— laboratory workload and testing capacities;
— compliance with recommended biosafety practices
and facility design;*
— participation in appropriate proficiency-testing
programs;
— systems and processes used for specimen referral and
transport;
— current laboratory testing algorithms and turn-
around times;
— rules for reporting results and providing isolates to
customers;
— ability to rapidly detect and guide treatment of
multidrug-resistant (MDR) TB cases; and
— the availability of a suitable workforce.
• Characterize information flow among laboratorians,
clinicians, and TB controllers regarding
— timeliness and effectiveness, and
— capacity to share information and data electronically.
• Identify relevant local, state, and federal regulations,
mandates, and policies for
— specimen referral, packaging, and transport;
— laboratory testing and reporting to specimen
submitters;
— reporting positive test results to public health officials;
— isolate disposition; and
— reimbursement procedures for services.
• Assess availability of training for laboratorians, TB-
control officials, and health-care providers.
• Assess costs in the public and private sectors for providing
— optimal specimen transport and referral systems
(e.g., courier services);
— laboratory services that meet recommended turn-
around times;
— state-of-the art TB test technologies in public and
private laboratories, as appropriate;
— training for laboratorians and health-care providers;
and
— optimal use of communication and information
management systems.
* Source: CDC; National Institutes of Health. Biosafety in
microbiological and biomedical laboratories. 4th ed. Washington, DC:
US Government Printing Office; 1999. Available at http://
www.cdc.gov/od/ohs/biosfty/bmb14/bmb14toc.htm.
BOX 1. Checklist for documenting tuberculosis (TB)
laboratory capacity and capability
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Strategic Planning
A strategic plan for implementing and maintaining a sys-
tems approach to TB control should be developed. Resources,
recommended testing algorithms for different patient popu-
lations, and guidelines should be developed to help each
jurisdiction select the appropriate level of services for each
public health system. The strategic plan should define action
steps and assign responsibility for action item completion. The
strategic plan should use a systems approach and involve all
partners to ensure development, implementation, and ongo-
ing assessment and improvement of a laboratory network that
provides critical capabilities (Box 2).
Outcome Measures
The following outcome measures should be used to assess
improvements in laboratory services and in overall TB-
control programs. A checklist of key performance indicators
is included (Box 3).
TB Incidence
Improvements in laboratory services should facilitate
progress toward elimination of TB and the accomplishment
of Healthy People 2010 objective 14-11, which calls for a rate
of less than one case per 100,000 persons (31). The labora-
tory contribution should be evaluated by monitoring 1) the
percentage of TB cases for whom microbiology laboratory test
results are entered in the Report of a Verified Case of Tuber-
A strategic plan for TB laboratory services should ensure
• communication and collaboration among all essential
partners;
• prompt, efficient reporting and tracking of information
throughout the system, including use of a system com-
patible with the National Electronic Disease Surveillance
System;*
• efficient referral of specimens and isolates in the public
and private sectors;
• use of optimally effective testing algorithms tailored to
jurisdictional needs;
• use of new technologies as appropriate;
• prompt detection and treatment of multidrug-resistant
(MDR) TB cases;
• rapid turnaround times for tests to facilitate moving
patients in or out of isolation;
• facilities and laboratory practices that comply with
biosafety recommendations;†
• a repository of TB isolates and access to genotyping
capability;
• compliance with all reporting requirements by all net-
work laboratories;
• a contingency plan for surge capacity in the event of an
emergency that might affect TB laboratory services;
• laboratory staff with technical proficiency to perform
rapid, high-quality testing; and
• integrated training activities involving laboratorians,
clinicians, and TB-control officials.
* Source: CDC. National Electronic Disease Surveillance System.
Atlanta, GA: US Department of Health and Human Services, CDC;
2004. Available at http://www.cdc.gov/nedss/index.htm.
† Source: CDC; National Institutes of Health. Biosafety in
microbiological and biomedical laboratories. 4th ed. Washington, DC:
US Government Printing Office; 1999. Available at http://
www.cdc.gov/od/ohs/biosfty/bmb14/bmb14toc.htm.
BOX 2. Developing a strategic plan for tuberculosis (TB)
laboratory services BOX 3. Performance indicators for assessing tuberculosis
(TB) laboratory services
The jurisdictional strategic plan should define action
steps, assign responsibility for action item completion, and
measure progress by using the following key indicators.
• TB incidence: Monitor laboratory contribution to TB
treatment and control within the jurisdiction.
• Promptness of treatment initiation: Monitor report-
ing of positive acid-fast bacilli (AFB) smear results.
• Timeliness of AFB-smear, culture, and drug-
susceptibility testing: Monitor use of recommended
methods and turnaround times.
• Efficiency and reliability of specimen and isolate
referral: Monitor written procedures and performance
of the referral system.
• Appropriate use of rapid-testing methods: Monitor
progress toward accomplishing Healthy People 2010
objective 14-14.*
• Availability of standard operating procedures: Moni-
tor completeness of written procedures for service
provision, specimen referral, and communication and
interaction among TB-control partners.
• Timeliness and completeness of information flow:
Monitor development and performance of an integrated
system that ensures prompt and accurate
communication.
• Completeness of isolate recovery for genotyping and
archiving: Monitor the percentage of TB patients for
whom an isolate has been archived.
• Effectiveness of training: Monitor performance im-
provements resulting from training.
* Source: US Department of Health and Human Services. Healthy
people 2010 (conference ed, in 2 vols). Washington, DC: US
Department of Health and Human Services; 2000. Available at http://
www.health.gov/healthypeople.
Vol. 54 / RR-6 Recommendations and Reports 7
culosis (RVCT); 2) the percentage of pulmonary or laryngeal
TB cases among persons aged >12 years for whom a sputum
culture was done and the data entered in the RVCT; and 3) the
percentage of culture-positive TB cases with drug-
susceptibility results entered in the RVCT.
Treatment Initiation
 All patients with newly diagnosed, highly infectious TB
(i.e., patients with positive acid-fast bacilli [AFB] smear test
results) should be started on appropriate treatment within 2
days of specimen collection. Progress toward this goal should
be evaluated by monitoring 1) the percentage of initial diag-
nostic specimens for which the date of the report of positive
results of AFB-smear microscopy to the health-care provider
is within 1 day of the date of specimen collection (35), and 2)
the average time to report the results.
AFB-Smear, Culture, and Drug-
Susceptibility Testing
Progress toward the goal of having all laboratories perform-
ing and reporting TB testing within the network in accor-
dance with CDC recommendations (15,16) should be
evaluated. Evaluation should include, at a minimum, moni-
toring the percentage of laboratories using recommended
methods for their level of service and the percentage of labo-
ratories meeting expedited turnaround times for reporting
results and referring specimens or isolates for additional testing.
Specimen and Isolate Referral
Written procedures for referring specimens and cultures and
for reporting results should be available. Performance of the
referral system should be monitored for time of specimen trans-
port, tracking of specimens and information, and time of
reporting results to submitting laboratories and health-care
providers.
Incorporation of Rapid-Testing Methods
Progress toward accomplishing Healthy People 2010 objec-
tive 14-14 (31), which sets a 2-day target for average labora-
tory turnaround time to confirm and report >75% of
culture-confirmed TB cases, should be evaluated by monitor-
ing the percentage of suspected TB patients for whom a rapid
test is performed, the average turnaround time for reporting
the results of a rapid test, and the percentage of newly diag-
nosed, culture-positive TB patients for whom the objective
is met.
Written Procedures for Interaction
with TB-Control Partners
The laboratory should have a document of understanding
that includes written procedures for service provision and com-
munication between the laboratory and TB-control partners,
including public health agencies, health-care providers, and
state TB-control officials. The document should be monitored
for completeness and should include detailed standard oper-
ating procedures for
• specimen submission (e.g., sample collection, transport,
and submission guidelines; standard submission forms;
specimen quality guidelines; and recommendations for
generating reminders for serial specimen submission);
• determining appropriateness of testing requests, includ-
ing guidelines for evaluating testing requests, communi-
cating with requestors, and requesting additional
information or specimens;
• results notification, including how and to whom test re-
sults (i.e., smear, culture identification, and drug-
susceptibility) should be reported;
• billing for services; and
• evaluating service provision and communication processes.
Efficient and Complete Flow of Information
To monitor development of an integrated system that en-
sures prompt, complete, and accurate communication, the
following factors should be evaluated:
• number and percentage of mycobacteriology laboratories
in a program area (measured by enrollment in a College
of American Pathologists or Clinical Laboratory Improve-
ment Act proficiency-testing program) that are partici-
pating in the laboratory system and those that are able to
share data electronically;
• number and percentage of TB clinicians who are aware of
the integrated system, and number and percentage who
participate in that system;
• percentage of culture-positive TB cases reported to the
TB-control program by the laboratory isolating the
M. tuberculosis bacteria, and average time to report to the
clinician and to the program; and
• percentage of TB cases for which the TB-control program
can identify the laboratory or laboratories at which initial
and referred diagnostic testing were performed with
respect to AFB-smear microscopy, culture identification,
and drug-susceptibility testing.
Isolate Recovery
The TB-control program should monitor the percentage of
TB patients with culture-positive results for whom the pro-
gram has obtained and archived an isolate.
Measurement of Training Outcomes
The program should conduct periodic training needs
assessments for laboratorians, clinicians, and TB-control
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officials, and should develop a plan for providing needed train-
ing. Training activities should be evaluated to determine which
modifications in operations and performance improvements
resulted from training.
Models of Network Collaboration
Because the provision of laboratory services is a local con-
cern, laboratorians and TB-control officials should work to-
gether to design a system to prioritize testing and maximize
resources to obtain prompt, reliable test results. The follow-
ing are examples of successful models for addressing certain
aspects of a successful laboratory network:
• The California Bactec™ MGIT™ (Mycobacteria Growth
Indicator Tube, produced by Becton, Dickinson and Com-
pany, Franklin Lakes, New Jersey) by-mail model uses an
efficient specimen referral system to balance the need for
rapid AFB-smear microscopy testing with the cost of pro-
viding rapid liquid culture and drug-susceptibility testing.
• The Michigan model illustrates steps in assessing needs,
strategic planning, integrating private and public labora-
tories, and using state-of-the-art communications systems
to improve the flow of information (36).
• The New York Fast Track model (37) provides access to
complex, state-of-the-art testing for all clinicians in a
jurisdiction.
• The North Dakota consolidation model centralizes test-
ing in the state laboratory to address concerns of workforce
competence and to maintain proficiency as the number
of specimens to be tested declines (38).
• The Washington State core laboratory model (39) ensures
high-quality services by a cooperative plan of consolidat-
ing testing in selected laboratories that provide compre-
hensive TB testing.
• The Wisconsin mycobacteriology laboratory program
involves a network that encourages voluntary adherence
to recommendations, oversight, and training through
regular site visits, and team building through annual
meetings (40).
California’s MGIT By-Mail Model
To address the need for rapid culture results while main-
taining rapid turnaround times for smear microscopy, the
California State Public Health Laboratory (CSPHL) imple-
mented a program in which CSPHL provides Bactec MGIT
tubes by mail to 10 rural public health laboratories. The labo-
ratories process specimens for mycobacterial smear and cul-
ture on-site, decreasing the turnaround time for reporting of
smear results. Processed specimens are inoculated onto solid
and MGIT culture media. Solid media are incubated and ex-
amined locally, but the MGIT tubes are mailed to CSPHL
for incubation. For positive MGIT cultures, identification is
performed by rapid methods, including DNA probes and
HPLC. Drug-susceptibility testing is performed by using the
radiometric Bactec method. Advantages of this system include
rapid availability of smear results locally, as well as access to
state-of-the-art rapid methods for culture identification and




The National Laboratory System (NLS) model (36), origi-
nally created for biologic and chemical terrorism prepared-
ness, is based on an integrated public-private laboratory system
that uses standard methods and engages in joint planning and
training activities. As one of four NLS pilot sites, Michigan
applied this model to multiple public health concerns, includ-
ing TB control. As part of the NLS process, Michigan’s state
laboratory convened partners (e.g., clinical microbiology labo-
ratory staff, regional public health laboratory directors, county
health department surveillance staff, infection-control special-
ists, physicians, physician assistants, and proficiency-testing
providers) in focus groups to identify the steps necessary to
build a statewide laboratory system to support response ac-
tivities for public health emergencies. Two critical concerns
were improving specimen transport and improving commu-
nications among partners.
In response to focus group discussions, the Michigan state
laboratory is pilot-testing a statewide courier system for over-
night delivery of specimens and AFB-positive broth cultures
to the state TB facility for rapid testing. The goals are to pro-
vide 1) 24-hour turnaround times for AFB-smear results and
rapid culture testing for laboratories that do not perform their
own testing and 2) rapid AFB identification and susceptibil-
ity testing to laboratories that perform rapid culture but do
not perform rapid identification tests. In addition, the state
public health laboratory is 1) developing a statewide, Internet-
based communication system, the Michigan Disease
Surveillance System, to provide epidemiologic and laboratory
information to health-care providers engaged in TB-related
work; 2) providing training in the standardized epidemiologic
and laboratory methods recommended by Healthy People 2010,
APHL, CDC, and ACET; and 3) partnering with commer-
cial laboratories and private health-care providers to expedite
submission of first isolates from new TB patients for rapid
susceptibility testing and molecular typing.
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New York State Fast Track
Referral Model
The Fast Track model program for TB was initiated by the
New York State Department of Health’s Wadsworth Labora-
tory in 1993 to expedite testing for highly infectious TB
patients (37). Approximately 165 laboratories within institu-
tions in New York are enrolled in the program. These labora-
tories process specimens for AFB smear and culture at the
local level to provide rapid smear results. Specimens from
patients whose smear is AFB-positive, who have a negative
smear but radiologic indications and clinical TB symptoms,
or who are suspected of having infection with MDR TB are
fast-tracked to the state public health laboratory for rapid
NAAT, liquid- and solid-media culture, and drug-
susceptibility testing.
The Fast Track system provides equal access statewide to
the latest rapid technology for detection and identification of
TB, even for facilities that routinely see no or limited num-
bers of TB cases. Additionally, this system helps ensure that
TB cases are reported rapidly by state laboratorians to health
department TB-control programs and that isolates are cap-
tured into the public health system for fingerprinting analysis
and outbreak investigation.
North Dakota Consolidation Model
The incidence of TB in North Dakota has declined to less
than one case per 100,000 state residents per year (2). Since
1993, the number of specimens sent to the state public health
laboratory for testing has declined steadily; by 2000, the state
laboratory received approximately 29 specimens per week —
a number low enough to generate concerns about staff profi-
ciency (19,20). In 2001, to address these concerns, the state
public health laboratory developed a strategic plan for TB labo-
ratory services (38). Elements of the plan included identify-
ing medical centers that were using out-of-state commercial
laboratories for TB testing, determining what services the state
laboratory needed to provide to compete with private labora-
tories, and improving relations with private clinical laborato-
ries in the state.
Beginning in 2001, state laboratorians implemented am-
plified direct testing with results available within 24 hours of
specimen receipt, modified their processing and testing sched-
ules to improve turnaround time, and met with staff in all
North Dakota medical centers to improve communication.
By educating partners in the state about the needs of the TB-
control program and the services the state laboratory could
provide, and by delivering reliable test results with rapid turn-
around times, the state laboratory centralized all North Da-
kota TB testing and increased its specimen volume to
>45 specimens/week. Moreover, consolidating testing at the




The Washington state core laboratory model, which debuted
in 1999, derived from an effort to coordinate delivery of labo-
ratory services within the state in the midst of health-care–
system reforms (39). The model ensures that all laboratories
have access to state-of-the-art TB testing by consolidating TB
diagnostic testing in three specialty laboratories — the state
public health laboratory and two urban hospital laboratories.
All three have access to up-to-date technology, and they ad-
here to recommended safety and reporting requirements.
Hospital and clinical laboratories are encouraged to submit
clinical TB specimens to one of the two core hospital labora-
tories. The state public health laboratory examines all clinical
specimens submitted by county health departments, serves as
the state TB reference laboratory, and maintains capacity to
conduct molecular epidemiology studies of TB isolates. It also
works with hospital and clinical laboratories that choose to
provide limited, on-site TB diagnostic services to ensure that
these laboratories meet national TB standards and are inte-
grated into the new delivery system. This model has reduced
the clinical workload at the state public health laboratory and
simultaneously reduced turnaround times for reporting smear,
culture, and drug-susceptibility test results (39).
Before initiating this system, state laboratorians evaluated
the TB diagnostic capacity and expertise in the state and also
examined alternative laboratory delivery systems for provid-
ing these services. The state public health laboratory
1) assembled a working group to evaluate possible causes of
delays in reporting positive test results, 2) surveyed laborato-
ries that provided TB testing to document the level of service
provided and technology being used, 3) conducted on-site
reviews of potential core specialty laboratories, and 4) hosted
meetings throughout the state to gather input and buy-in from




The Wisconsin Mycobacteriology Laboratory Network
(WMLN) (40), sponsored by the Wisconsin State Laboratory
of Hygiene (WSLH) and the state TB-control program, links
clinical laboratories with the public health system. WMLN
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provides data sharing so that all TB-control partners receive
regular reports on case counts, outbreaks, and resistance trends.
Certain services (i.e., NAAT, HPLC, and TB identification
and molecular genotyping) are centralized at WSLH. State
laboratorians provide technical training to clinical laborato-
ries, as well as serve as a repository for all TB isolates. The TB
network also enhances preparedness for biologic terrorism,
because clinical laboratories are prepared to process the TB
testing provided by state laboratorians and provide personnel
trained in Biosafety Level 3 practices for biologic-specimen
processing in the event of a terrorist attack.
Development of the network began in 1997 with a survey
of laboratorians, clinicians, and public health professionals to
evaluate the role of all state laboratories in TB prevention and
control. In 1998, a position paper was written by staff from
the Wisconsin Tuberculosis Control Program to describe prac-
tices and make recommendations to achieve consistent, high-
quality testing in all laboratories performing TB testing. The
recommendations addressed appropriate use of NAAT,
laboratory safety, staff proficiency, problems with cross-
contamination, and quality assurance. Beginning in 1999,
network members promoted compliance with these
recommendations through a series of site visits by WSLH staff




The recommendations of the APHL Task Force on the
Future of TB Laboratory Services have been approved by the
APHL Board of Directors and endorsed by ACET. To ensure
their widespread dissemination and implementation, key TB-
control partners should take the following steps:
• APHL, CDC, and members of the Task Force should seek
partnerships with professional organizations (including
the College of American Pathologists [CAP], American
Society for Clinical Pathology, ASM, American Clinical
Laboratory Association, NTCA, National Committee of
Clinical Laboratory Standards, and others) to ensure fur-
ther implementation throughout the health-care system.
• ACET and its partner organizations should educate policy
makers (including federal and state legislators and
National Governors’ Association officers) about steps nec-
essary to eliminate TB in the United States.
• In collaboration with the National Laboratory Training
Network, ASM, CAP, NTCA, APHL, and CDC should
develop and deliver integrated training courses to address
laboratory, clinical, and TB-control topics.
• APHL and NTCA should build a stronger partnership
and take advantage of opportunities to exchange infor-
mation among their members at national, regional, and
local meetings and training forums.
• Clinicians, laboratorians, and public health authorities
(including representatives of NTCA, APHL, and ATS)
should work together to develop templates that are
appropriate for high- and low-incidence regions and that
include
— recommendations for levels of service;
— standardized laboratory education materials for clini-
cians, laboratory staff, public health personnel, and
patients;
— standardized laboratory requisitions (which might also
be used to educate partners);
— notification algorithms;
— cost-assessment protocols;
— process development (e.g., for analysis and improve-
ment in turnaround time); and
— quality oversight for optimal system performance.
Research Needs
Continual improvement in the quality of laboratory ser-
vices requires investment in and conduct of public health-
related research, including 1) operational research to support
science- and experience-based recommendations for labora-
tory services that provide for effective patient management
and population-based TB control, 2) cost-benefit analysis for
various types of services and technologies, and 3) collabora-
tive technical research to develop and drive the implementa-
tion of innovative technologies.
Conclusion
To eliminate TB in the United States, clinicians, TB-
control officials, and public health officials need access to
prompt and reliable TB laboratory services. Delayed labora-
tory confirmation of TB leads to delays in initiation of therapy,
potentially inappropriate therapy, and missed opportunities
to prevent transmission. Although provision of laboratory ser-
vices is a jurisdictional matter and can be organized at the
local, state, or regional level, any successful effort to provide
prompt, reliable laboratory services should involve assessment
and understanding of the structure, performance, and cost of
the network of laboratory service providers and users; devel-
opment of a referral and information network to ensure reli-
able testing and prompt flow of specimens and information;
and use of quality-improvement principles to continually
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evaluate and improve the performance of the laboratory
service network.
A systems approach is necessary to optimize laboratory TB
testing and information exchange and to ensure that appro-
priate services are available in every program. Laboratorians,
clinicians, public health officials, administrators, and funders
should collaborate to ensure that health-care providers and
TB-control officials have the information they need to treat
TB patients, prevent TB transmission, and ultimately elimi-
nate the disease in the United States. The full report of the
APHL Task Force on the Future of TB Laboratory Services
(34) provides additional information on the role of the public
health laboratory in TB treatment and control, additional
background on the Task Force processes, further guidance on
developing a system for providing TB laboratory services, and
steps for dissemination and implementation of the Task Force
recommendations.
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